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Abstract
 
The peroxisome proliferator–activated receptor 
 
g
 
 (PPAR
 
g
 
) is highly expressed in the colon
mucosa and its activation has been reported to protect against colitis. We studied the involve-
ment of PPAR
 
g
 
 and its heterodimeric partner, the retinoid X receptor (RXR) in intestinal in-
flammatory responses. PPAR
 
g
 
1
 
/
 
2
 
 and RXR
 
a
 
1
 
/
 
2
 
 mice both displayed a significantly enhanced
susceptibility to 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis compared with
their wild-type littermates. A role for the RXR/PPAR
 
g
 
 heterodimer in the protection against
colon inflammation was explored by the use of selective RXR and PPAR
 
g
 
 agonists. TNBS-
induced colitis was significantly reduced by the administration of both PPAR
 
g
 
 and RXR ago-
nists. This beneficial effect was reflected by increased survival rates, an improvement of macro-
scopic and histologic scores, a decrease in tumor necrosis factor 
 
a
 
 and interleukin 1
 
b
 
 mRNA
levels, a diminished myeloperoxidase concentration, and reduction of nuclear factor 
 
k
 
B DNA
binding activity, c-Jun NH
 
2
 
-terminal kinase, and p38 activities in the colon. When coadminis-
tered, a significant synergistic effect of PPAR
 
g
 
 and RXR ligands was observed. In combina-
tion, these data demonstrate that activation of the RXR/PPAR
 
g
 
 heterodimer protects against
colon inflammation and suggest that combination therapy with both RXR and PPAR
 
g
 
 ligands
might hold promise in the clinic due to their synergistic effects.
Key words: colitis • inflammatory bowel disease • nuclear receptors • tumor necrosis factor 
 
a
 
 • 
signal transduction pathway
 
Introduction
 
The peroxisome proliferator–activated receptor 
 
g
 
(PPAR
 
g
 
)
 
1 
 
is a nuclear receptor that controls the expression
of several genes involved in metabolic control. PPAR
 
g
 
 is
activated by fatty acid derivatives, thiazolidinediones, and
certain nonsteroidal antiinflammatory drugs (1–3). Thiazo-
lidinedione PPAR
 
g
 
 agonists, such as troglitazone, rosiglita-
zone, and pioglitazone, have been or are currently being
used as insulin-sensitizing drugs in the treatment of the
type 2 diabetes (4). In addition to these effects on glucose
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Abbreviations used in this paper:
 
 IBD, inflammatory bowel disease; JNK,
c-jun NH
 
2
 
-terminal kinase; MAPK, mitogen-activated protein kinase;
MPO, myeloperoxidase; NF, nuclear factor; PPAR
 
g
 
, peroxisome prolif-
erator–activated receptor 
 
g
 
; RXR, retinoid X receptor; TNBS, 2,4,6-
trinitrobenzene sulfonic acid.
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homeostasis, in vitro studies have shown that PPAR
 
g
 
 acti-
vators could have antiinflammatory effects. PPAR
 
g
 
 activa-
tors were able to limit the production of inflammatory me-
diators such as inflammatory cytokines produced by human
activated monocytes-macrophages and intestinal epithelial
cells through an inhibition of transcription driven by nu-
clear factor (NF)-
 
k
 
B and activating protein 1 (AP-1) tran-
scription factors (5–7). Recently, PPAR
 
g
 
 agonists have
been reported to attenuate colitis in a murine model in
which inflammation was induced by administration of dex-
tran sodium sulfate (7). This observation suggested that
PPAR
 
g
 
 activators may be useful in the treatment of pa-
tients with inflammatory bowel disease (IBD). IBD encom-
passes several chronic diseases, which are characterized at
least in part by an overproduction of pathogenic inflamma-
tory cytokines such as TNF-
 
a
 
 and IL-1
 
b
 
, leading to the
activation of the NF-
 
k
 
B and c-Jun NH
 
2
 
-terminal kinase
(JNK)/p38 mitogen-activated protein kinase (MAPK)
pathways (8–10).
To activate transcription, PPAR
 
g
 
 requires heterodimer-
ization with the retinoid X receptor (RXR). The RXR/
PPAR
 
g
 
 heterodimers are permissive to activation by both
PPAR
 
g
 
 and RXR ligands. Therefore, several of the bio-
logical effects of PPAR
 
g
 
 activation, such as insulin sensiti-
zation, can be reproduced by specific RXR agonists or
rexinoids. Proof of a role for the RXR/PPAR
 
g
 
 het-
erodimer in intestinal inflammation has been limited to
pharmacological studies demonstrating the efficacy of
PPAR
 
g
 
 agonists. In this study, we investigated the poten-
tial effects of both PPAR
 
g
 
 and RXR in an experimental
animal model in which colitis was induced by intrarectal
administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS).
We provide genetic evidence of an involvement of both
PPAR
 
g
 
 and RXR in colon inflammation, by showing that
PPAR
 
g
 
1
 
/
 
2
 
 and RXR
 
a
 
1
 
/
 
2
 
 mice were significantly more
susceptible to inflammation than their wild-type litter-
mates. Furthermore, we confirm the protective effects of
PPAR
 
g
 
 ligands in a different experimental colitis model
than the one used by Su et al
 
. 
 
(7). Most importantly, we
demonstrate for the first time that RXR agonists were
equally effective as PPAR
 
g
 
 agonists in reducing intestinal
inflammation. In addition, rexinoids have a marked syner-
gistic effects with PPAR
 
g
 
 agonists on inflammation. In
combination, our data emphasize the importance of both
partners of the RXR/PPAR
 
g
 
 heterodimer in the regula-
tion of colon inflammation. The synergistic antiinflamma-
tory activities of RXR and PPAR
 
g
 
 agonists suggests that
coadministration of low doses of PPAR
 
g
 
 and RXR ago-
nists might be worth exploring in human IBD.
 
Materials and Methods
 
Materials
 
The PPAR
 
g
 
 and RXR agonists were synthesized at Ligand
Pharmaceuticals. TNBS was purchased at Fluka.
 
Induction of Colitis and Study Design
 
Animal experiments were performed in accredited establish-
ments (N
 
8
 
 B59-108 and B67-218-5) according to governmental
guidelines N
 
8
 
86/609/CEE. Animals were group housed (6–8/
cage) and had free access to regular rodent chow and tap water.
For induction of colitis, mice, which were anesthesized for 90–
120 min, received by intrarectal administration 40 
 
m
 
l of a solu-
tion of TNBS (150 mg/kg) dissolved in 0.9% NaCl and mixed
with an equal volume of ethanol (50% ethanol). Control mice re-
ceived 50% ethanol or a saline solution using the same technique.
Animals were killed by cervical dislocation 2 or 5 d after TNBS
administration. First, wild-type male Balb/c mice were used in
the intervention studies with the PPAR
 
g
 
 and RXR agonists,
rosiglitazone (5–50 mg/kg/day), troglitazone (50–200 mg/kg/
day), or LG101305 (5–50 mg/kg/day). These compounds were
administered once daily by oral gavage (11), starting either 2 d
before (preventive mode) or just after the induction of colitis
(therapeutic mode). A general outline of the different intervention
studies is represented in Fig. 1. In a second set of experiments,
PPAR
 
g
 
1
 
/
 
2
 
 and RXR
 
a
 
1
 
/
 
2
 
 mice or their respective wild-type lit-
termates (both on a 129/Sv background) were used. Heterozy-
gote mice were used because homozygous PPAR
 
g
 
2
 
/
 
2
 
 and
RXR
 
a
 
2
 
/
 
2
 
 mice are embryonic lethal. These 129/Sv mice were
killed 2 d after the induction of colitis.
 
Macroscopic and Histologic Assessment of Colitis
 
The colon was examined under a dissecting microscope (
 
3
 
5)
to evaluate the macroscopic lesions according to the Wallace cri-
Figure 1. Design of the animal intervention
studies. TNBS (black ellipse) was administered in-
trarectally on day (D) 0 and mice were killed 2 or
5 d later. The rexinoid (LG101305), the PPARg ag-
onists, such as rosiglitazone and troglitazone, or the
combination of a rexinoid and a PPARg agonist
were administered at the indicated doses 2 d before
the induction of colitis (preventive mode). The
therapeutic effects were evaluated in mice receiving
the same dose of rosiglitazone just after TNBS ad-
ministration (therapeutic mode). Treatment with
PPARg and/or RXR agonists was evaluated at day
2 or 5 by scoring for mortality, determination of
macroscopic and histologic inflammation scores,
and measurements of inflammatory parameters
(MPO levels, TNF-a and IL-1b mRNA, NF-kB
pathway, and MAPK activity).
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teria. The Wallace score rates macroscopic colon lesions on a
scale from 0 to 10 based on criteria reflecting inflammation, such
as hyperemia, thickening of the bowel, and the extent of ulcer-
ation (12). A colon specimen located precisely 2 cm above the
anal canal was cut into four parts. One part was fixed overnight in
4% paraformaldehyde acid and embedded in paraffin. Sections
stained with hematoxylin and eosin were examined blindly by a
pathologist and scored according to the Ameho criteria (13). This
grading on a scale from 0 to 6 takes into account the degree of
the inflammatory infiltrate, the presence of erosion, ulceration or
necrosis, and the depth and surface extension of the lesions (13).
The other parts of the colon were used for quantification of
TNF-
 
a
 
 and IL-1
 
b
 
 mRNA, myeloperoxidase (MPO), and NF-
 
k
 
B DNA binding or MAPK activities.
 
Table I.
 
Mouse Oligonucleotide Sequences
 
Primer Sequence
TNF-
 
a
 
 AS 5
 
9
 
-GGG-AGT-AGA-CAA-GGT-ACA-AC-
 
3
 
9
 
TNF-a S 59-TCT-CAT-CAG-TTC-TAT-GGC-CC-39
IL-1b AS 59-AGA-AGG-TGC-TCA-TGT-CCT-CAT-39
IL-1b S 59-TTG-ACG-GAC-CCC-AAA-AGA-TG-39
AS, antisense; S, sense.
Figure 2. TNBS-induced colitis is dose-depen-
dently improved by PPARg agonists. (A) Macroscopic
appearance of the colon of mice receiving vehicle only
(Control), TNBS, or mice receiving rosiglitazone (20
mg/kg/d) 2 d before the administration of TNBS
(Rosiglitazone 1 TNBS). The bottom shows a larger
magnification of the colon at the injection site. (B and
C) The antiinflammatory effects of different doses of
troglitazone (B) and rosiglitazone (C) were assessed
preventively in TNBS-induced colitis. The severity of
the lesions was evaluated by macroscopic and histo-
logic assessments using, respectively, the Wallace and
Ameho scores in mice killed 2 d after colitis induction.
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Quantification of Protein and mRNA Expression in the Colon
Protein preparation and immunoblotting were performed as
described (14). Total protein extracts were obtained by homoge-
nization of tissues in an extraction buffer consisting of PBS with
1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, and a classical protease inhibitor cocktail. Total proteins
were then separated by PAGE and electroblotted (14). Immuno-
detection with a secondary peroxidase-conjugated antibody and
chemiluminescence was performed according to the manufac-
turer’s protocol (ECL; Amersham Pharmacia Biotech). RNA was
isolated from colon samples with the TRIzol reagent as described
(15). After treatment at 378C for 30 min with 20–50 units of
DNase I RNase-free (Boehringer), total RNA (5–10 mg) was re-
verse transcribed into cDNA. The reverse transcription reaction
mixture was amplified by PCR using sense and antisense primers
specific for TNF-a and IL-1b (Table I; references 15 and 16).
The samples were subjected to 40 PCR cycles (PerkinElmer).
Quantification of cytokine cDNA was performed by electro-
phoresis in 2–3% agarose gel using an image analyzer (Gel Ana-
lyst; Clara Vision; reference 17). Results of cytokine measure-
ments were expressed in proportion to the quantity of total
RNA, in the same sample.
Quantification of NF-kB DNA Binding, JNK, and p38 Kinase 
Activities in the Colon
NF-kB Electromobility Shift Assay. Cellular protein extracts
were prepared by homogenizing the colon in the following
buffer: 20 mM Hepes, pH 7.9, 350 mM NaCl, 1 mM MgCl2, 0.5
mM EDTA, 0.5 mM dithiothreitol, 0.1 mM EGTA, 20% glyc-
erol, 1% NP-40, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluo-
ride hydrochloride (AEBSF), 2 mg/ml aprotinin, and 10 mM leu-
peptin. In vitro binding reactions of NF-kB in a total volume of
25 ml were initiated by incubation of 5 mg of nuclear protein ex-
tracts in a binding buffer containing 10 mM Hepes, pH 7.5, 50
mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 1 mM MgCl2,
5% glycerol, 2 mg poly(dI-dC), and 0.4 mg/ml salmon sperm
DNA (18). After 10 min of preincubation on ice, 50,000–
100,000 cpm of 32P end-labeled NF-kB oligonucleotide probe
(59-GATCCAAGGGACTTTCCATG-39 corresponding to the
NF-kB binding sequence of the human IL-2 promoter) were
added and the binding reaction was allowed to proceed for 20
min at 218C. Then, DNA–protein complexes were resolved by
electrophoresis on Tris-acetic acid-EDTA (TAE)-4% polyacryla-
mide gels at 48C, and analyzed by autoradiography. As control, a
50-fold molar excess of cold NF-kB competitor oligonucleotide
was added during preincubation.
JNK or p38 Kinase Assay. Colon was homogenized in TLB
(triton lysis buffer): 20 mM Tris, pH 7.5, 137 mM NaCl, 2 mM
EDTA, pH 7.5, 1% Triton X-100, 25 mM b-glycerophosphate,
1 mM Na orthovanadate, 2 mM NaPPi, 10% glycerol, 1 mM
PMSF, and 10 mg/ml leupeptin. Soluble extracts were prepared
by centrifugation at 12,000 rpm for 30 min at 48C. The extracts
(300 mg of protein) were incubated with 2 ml of anti-JNK or
anti-p38 rabbit serum prebound to protein A-Sepharose (19). Af-
ter 1 h of incubation at 48C, the immunoprecipitates were
washed twice with TLB and twice with kinase buffer: 25 mM
Hepes, pH 7.5, 25 mM MgCl2, 25 mM b-glycerophosphate, 2
mM dithiothreitol (DTT), and 0.1 mM Na orthovanadate. Im-
mune complex kinase assays were performed at 308C for 20 min
using 2 mg of glutathione-S-transferase (GST)-activating tran-
scription factor (ATF)2(1-109), 50 mM ATP, and 3–10 mCi of
[g-32P]ATP as substrates in 20 ml of kinase buffer (20). The reac-
tions were terminated with Laemmli sample buffer, the products
were resolved by SDS-PAGE (12%), and quantified after autora-
diographic analysis as described (20).
Statistics
All comparisons were analyzed by the nonparametric Kruskal-
Wallis one-way analysis of variance (ANOVA) test. Differences
were judged statistically significant if the P value was ,0.05.
Results
TNBS-induced Colitis Is Improved by PPARg Agonists.
First, we characterized the development of colitis in ani-
mals subjected to TNBS injection. Whereas control mice,
killed 2 or 5 d after administration of 50% ethanol or a sa-
line solution, had no macroscopic lesions in the colon, a se-
vere colitis was induced as early as 2 d after administration
of TNBS, resulting in death in 22 6 6% of the animals
(Fig. 2 A, and Table II). 5 d after induction of colitis, the
Table II. Preventive Administration of Rosiglitazone or Troglitazone Have Similar Therapeutic Effects on Colitis 2 d after
TNBS Administration
Control
(n 5 16)
TNBS
(n 5 23)
Rosiglitazone
(n 5 14)
on TNBS-induced colitis
Troglitazone
(n 5 8)
on TNBS-induced colitis
Mortality 0% 22 6 6% 12.5 6 12.5% 10.2 6 8%
Wallace score 0 6 0 7.14 6 0.86* 3.6 6 2‡ 3.8 6 1.5§
Ameho score 0 6 0 5.5 6 0.5* 2.3 6 1.2‡ 2.5 6 1§
MPO values 2.5 6 3.6 34 6 16* 14 6 20‡ 18 6 14§
TNF-a mRNA 0.84 6 0.81 3.91 6 3.94* 0.58 6 0.69i 0.45 6 0.74§
IL-1b mRNA 0.32 6 0.26 28.5 6 31.1* 4 6 3i 4 6 4§
*Denotes a P , 0.001 between control and TNBS-induced colitis.
‡Denotes a P , 0.01 between TNBS-induced colitis and mice with colitis treated with rosiglitazone.
§Denotes a P , 0.01 between TNBS-induced colitis and mice with colitis treated with troglitazone.
iDenotes a P 5 0.001 between TNBS-induced colitis and mice with colitis treated with rosiglitazone.
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lesions were more severe with necrosis of the colon leading
to mortality in 68 6 4% of the animals. On a histologic
level, no abnormalities were detected in control mice (Fig.
3 A). In sharp contrast, 2 d after the administration of
TNBS, colon histology was characterized by large areas of
ulceration with a neutrophilic infiltrate, necrosis extending
deeply into the muscular layer (Fig. 3, B and C), and en-
hancement of MPO levels, a marker of neutrophil content
(21; Fig. 4). Necrosis of the colon in mice surviving 5 d af-
ter TNBS administration involved z90% of the specimen,
and was so severe that it precluded evaluation of other pa-
rameters such as MPO, TNF-a, and IL-1b mRNA levels,
and activity of NF-kB.
We then evaluated the effects of PPARg activation on
TNBS-induced colon lesions by performing a detailed dose–
response study, using two different synthetic PPARg agon-
ists, i.e., troglitazone (Fig. 2 B; from 50 to 200 mg/kg/day)
and rosiglitazone (Fig. 2 C; from 5 to 50 mg/kg/day). In the
first experiments, PPARg agonists were used in a preventive
mode and administered 2 d before colon lesions were in-
duced. When animals were analyzed 2 d after the induction
of colitis, both PPARg agonists significantly reduced mor-
tality compared with untreated mice with colitis and im-
proved macroscopic and microscopic aspects of the TNBS-
induced colon lesions (Fig. 2 and Table II). Optimal effects
were obtained with a dose of 150–200 mg/kg/d of troglita-
Figure 3. Representative histological sections of colon tissues of Balb/c mice. (A) Normal transparietal colon section of a vehicle-treated mouse with
an Ameho score of 0 (3250). The different layers are indicated: M, mucosa; SM, submucosa; Mu, muscular layer. (B) Transparietal colon section
(Ameho score 6) 2 d after the induction of colitis by TNBS. Thickening of the colon wall, with a predominant inflammatory infiltrate in the lamina pro-
pria, and necrosis extending deeply into the muscular and serosal layers are evident (3400). (C) Transparietal colon section (Ameho score 6) 5 d after the
induction of colitis by TNBS. Parietal necrosis extending deeply into the muscular layer with the disappearance of cells in the mucosa is visible (3250).
(D) Transparietal colon section of a mouse, which received rosiglitazone before TNBS administration. The mouse was killed 2 d after colitis induction.
The Ameho score was graded 2. The picture shows a subepithelial edema with a diastasis of the crypts and a moderate inflammatory infiltrate in the mu-
cosa and submucosa (3250). (E) Transparietal colonic section of mice treated with rosiglitazone after administration of TNBS. The pictures show mice
killed 5 d after colitis induction. Ulceration extending into the submucosa, associated with a mucosal, submucosal, and muscular inflammatory infiltrate
involving ,50% of the specimen, is visible (3250). (F and G) Colon sections of mice that received rosiglitazone before TNBS administration. The mice
were killed 2 d after colitis induction. In some cases, a total repair of the mucosa was observed (F; 3600) despite the persistence of an in-depth focal ne-
crosis in the submucosal layer (G; 3400).
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zone and 20–50 mg/kg/d of rosiglitazone (Fig. 2, B and C).
Consistent with their efficacy and potency as PPARg ago-
nists in transfection assays, rosiglitazone was both a more po-
tent and more efficacious antiinflammatory compound than
troglitazone. These optimal doses were used in all following
experiments. 5 d after induction of colitis, a significant de-
crease in both mortality and macroscopic lesion score was
observed in mice that had received rosiglitazone preven-
tively compared with untreated mice with colitis (Table III).
Parallel to the gross macroscopic inflammation, histologi-
cal analysis also revealed major differences between TNBS
animals and animals receiving PPARg agonists (Fig. 3, B
and D). This was reflected by a significant decrease of the
Ameho inflammation score both at 2 (Fig. 4 B) and 5 d (Ta-
ble III) after TNBS administration. Administration of
PPARg agonists dramatically reduced the inflammatory le-
sions, which consisted of smaller polymorphic inflammatory
infiltrates, with mononuclear predominance, limited edema,
and small focal necrotic lesions in close contact to regions
with reepithelialization of the mucosal layer (Fig. 3 D). This
improvement by the preventive administration of rosiglita-
zone was associated with a significant decrease of MPO lev-
els 2 d after TNBS administration (Fig. 4 C). Interestingly,
in certain cases, total repair of the mucosal and muscularis
mucosa layers was observed despite the persistence of some
in-depth lesions (Fig. 3 F). These lesions were either in the
form of a mononuclear infiltrate in the submucosa and the
muscular layers, or in some cases in the form of focal necro-
sis of the ischemic type in the muscular layer (Fig. 3 G).
In the experiments described above, administration of
PPARg agonists started before TNBS was administered.
Therefore, we next analyzed whether the administration of
Figure 4. Effect of PPARg and RXR agonists on TNBS-induced
colitis. Wallace macroscopic inflammation score (A), Ameho histologic
score (B), and colon MPO levels (C) of mice receiving vehicle only
(Control), TNBS, rosiglitazone (Rosi at 20 mg/kg/d), LG101305 (LG at
20 mg/kg/d), or rosiglitazone and LG101305 simultaneously (Rosi 1 LG
both at 20 mg/kg/d) 2 d before the administration of TNBS. The num-
ber of mice is indicated and results are expressed as the mean 6 SEM.
Animals were killed 2 d after TNBS treatment. (a) P , 0.001 in control
mice vs. untreated TNBS colitis; (b) P , 0.001 and (c) P 5 0.009 in un-
treated TNBS colitis vs. mice receiving rosiglitazone; (d) P 5 0.002 and
(e) P , 0.001 in untreated TNBS colitis vs. mice receiving LG101305;
and (f) P , 0.001 in untreated TNBS colitis vs. mice receiving both
rosiglitazone and LG101305.
Table III. Rosiglitazone Used in a Preventive or Therapeutic 
Modes Improved Colitis 5 d after TNBS Administration
Rosiglitazone on
TNBS-induced colitis
Control
(n 5 16)
TNBS
(n 5 14)
Preventive
mode
(n 5 16)
Therapeutic
mode
(n 5 16)
Mortality 0 6 0% 68 6 4%* 19 6 9%‡ 14 6 8%‡
Wallace score 0 6 0 8.9 6 1.4* 3.5 6 0.6‡ 5.8 6 0.9§
Ameho score 0 6 0 6 6 0* 2.1 6 1.1‡ 4.1 6 0.7i
*P , 0.0001 between control and TNBS-induced colitis.
‡P , 0.0001 between TNBS-induced colitis and mice with colitis
treated with rosiglitazone.
§P 5 0.02 between TNBS-induced colitis and mice with colitis treated
with rosiglitazone.
iP 5 0.001 between TNBS-induced colitis and mice with colitis
treated with rosiglitazone.
Figure 5. PPARg-RXR agonists have a synergistic effect on colitis.
The antiinflammatory effects of different doses of the RXR agonist
LG101305 (A) and of the simultaneous administrations of rosiglitazone
(from 1 to 20 mg/kg/d) and LG101305 (from 1 to 20 mg/kg/d)(B) were
assessed in TNBS-induced colitis. The severity of the lesions was evalu-
ated by macroscopic and histologic assessments using, respectively, the
Wallace and Ameho scores in mice killed 2 d after colitis induction.
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rosiglitazone immediately after the induction of colitis was
also effective in reducing lesion intensity. In this therapeu-
tic mode, rosiglitazone also significantly improved the mac-
roscopic lesions and mortality compared with untreated
mice with colitis (Table III). This macroscopic improve-
ment was again associated with a significant decrease of the
histologic score (Table III and Fig. 3 E). These data prove
that PPARg agonists can not only prevent lesion develop-
ment, but are also effective in reducing established inflam-
matory lesions in the colon.
RXR Agonist Synergizes with PPARg Agonists in Improving
Colitis. As PPARg forms a “permissive” heterodimer
with RXR, we next used the selective and potent RXR
agonist LG101305 to analyze whether activation of RXR
could mimic any of the beneficial effects of PPARg activa-
tion on TNBS-induced colon lesions. In dose–response
studies, LG101305 at a dose of 50 mg/kg/d achieved a
maximal effect similar to that as observed with the maxi-
mally efficacious dose of rosiglitazone (Figs. 2 C and 5 A).
This improvement was associated with a significant de-
crease in the histologic lesion score and a normalization of
MPO levels (Fig. 4, B and C).
As the above data demonstrated that both PPARg and
RXR agonists are effective in the treatment of colitis, we
next assessed whether the combination of LG101305 with
rosiglitazone could have synergistic beneficial effects on the
Figure 6. PPARg1/2 and RXRa1/2
mice are more susceptible to TNBS-
induced colitis. (A and B) Wallace macro-
scopic and Ameho histologic inflammation
scores of 129/Sv wild-type (WT),
PPARg1/2 (A) and RXRa1/2 (B) mice 2 d
after induction of colitis by TNBS adminis-
tration. (C) Representative transparietal co-
lon section of 129/Sv wild-type mice
(Ameho score 5) 2 d after the induction of
colitis by TNBS showing a moderate infil-
trate with a necrosis limited to the superficial
part of the mucosa (3200). (D and E)
Transparietal colon sections in PPARg1/2
(D) and RXRa1/2 (E) mice (both Ameho
scores of 6) 2 d after the induction of colitis
by TNBS. Thickening of the colon wall
with a marked transparietal inflammatory in-
filtrate and necrosis (3200). Mean 6 SEM
are indicated, the number of mice, as well as
the statistical significance are indicated.
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TNBS-induced colitis. When both these agonists were
given preventively at doses of 1–20 mg/kg/d, striking mac-
roscopic and histologic improvements of TNBS-induced
colitis were observed (Fig. 5 B), suggesting a synergistic ef-
fects of these two agonists. In fact, lesions were often al-
most absent and submucosal neutrophil infiltrate was mod-
est, with very low MPO activity (Fig. 4 C). The synergism
was best illustrated by the efficacy of the combination of
PPARg and RXR ligands at a dose of 1 mg/kg/d each,
which is 1/20e of the maximally efficacious dose of each
individual agonist, and which still retained a remarkable an-
tiinflammatory effect (Figs. 4 and 5 B).
Increased Susceptibility of PPARg1/2 and RXRa1/2 Mice to
TNBS-induced Colitis. As the above intervention studies
using PPARg and RXR agonists were suggestive of the
involvement of the RXR/PPARg heterodimer in improv-
ing colitis, we next tested whether mice heterozygous for a
deficiency of PPARg and/or RXRa were more suscepti-
ble to the development of TNBS-colitis. These heterozy-
gous knockout mice and their wild-type littermates are on
a 129/Sv background. Relative to Balb/c mice, TNBS in-
duced a less severe colitis in 129/Sv mice (compare abso-
lute macroscopic and histologic lesion scores in Figs. 4
and 6; P , 0.001). Relative to PPARg1/1 littermates,
PPARg1/2 mice had more pronounced macroscopic and
microscopic lesions with an enhancement of MPO levels
(data not shown) after a challenge with TNBS (Fig. 6).
These lesions were characterized by large and deep ulcer-
ations with a necrosis and inflammatory infiltrate extending
deeply into the muscular layer (Fig. 6 D). Relative to the
RXRa1/1 mice, the RXRa1/2 mice developed also sig-
nificantly more intense macroscopic and histologic lesions
after TNBS administration (Fig. 6, B and E). Like for the
PPARg1/2 mice, this increased susceptibility to lesion for-
mation was associated with a dramatic induction of MPO
levels (data not shown) in the colon and a necrosis which
involved z90% of the specimen (Fig. 6, B and E). In com-
bination with the data obtained using PPARg and RXR
agonists (Figs. 2–5), these studies in PPARg and RXRa1/2
mice implicate the RXR/PPARg heterodimer in the pro-
tection against intestinal inflammation.
PPARg and RXR Agonists Inhibit Inflammatory Cytokine
Expression and NF-kB and JNK/p38 MAPK Activities. Al-
though all the above data underscore the importance of the
Figure 7. TNF-a and IL-1b mRNA levels are re-
duced by PPARg and RXR agonists. TNF-a (A)
and IL-1b (B) mRNA levels in the colon of mice re-
ceiving vehicle only (Control), TNBS, rosiglitazone
(Rosi at 20 mg/kg/d), LG101305 (LG at 20 mg/kg/
d), or simultaneous administration of rosiglitazone
and LG101305 (Rosi 1 LG both at 1 mg/kg/d) 2 d
before the administration of TNBS. Animals were
killed 2 d after TNBS administration. Results are ex-
pressed as mean 6 SEM. mol, molecules. (A): (a)
P , 0.001 in control vs. TNBS; (b) P 5 0.001 in
untreated TNBS colitis vs. mice receiving rosiglita-
zone; (c) P 5 0.076 in untreated TNBS colitis vs.
mice receiving LG101305; and (d) P 5 0.05 in un-
treated TNBS colitis vs. mice receiving both rosigli-
tazone and LG101305. (B): (a) P , 0.001 in control
vs. TNBS; (b) P 5 0.001 in untreated TNBS colitis vs. mice receiving rosiglitazone; (c) P 5 0.003 in untreated TNBS colitis vs. mice receiving
LG101305; and (d) P 5 0.003 in untreated TNBS colitis vs. mice receiving both rosiglitazone and LG101305.
Figure 8. NF-kB, JNK, and p38 kinase activities
2 d after TNBS colitis induction in mice treated
preventively with rosiglitazone. (A) NF-kB. Pro-
teins in colon homogenates obtained from three
control mice (Control), three mice receiving TNBS
(TNBS), and three mice receiving TNBS and
rosiglitazone (Rosi, 20 mg/kg/day) were used in
electrophoretic mobility shift assay (EMSA) reac-
tions as described in Materials and Methods. The
top panel shows autoradiographs of the EMSA assay
using a radiolabeled NF-kB consensus binding site.
The bottom panel shows a graphical presentation
obtained after scanning the corresponding autorad-
iographs. Compared with the most intense NF-kB
complex radiolabeled signal obtained in mice re-
ceiving TNBS, control (Cont) corresponding to a
competition with an excess of cold NF-kB showed
a marked decrease of the radiolabeling. (B and C)
JNK (B) and p38 kinase (C) activities in immunoprecipitates of colon extracts obtained from three control mice (Control), three mice receiving TNBS
(TNBS), and three mice receiving TNBS and treated preventively with rosiglitazone (Rosi, 20 mg/kg/day). The top panel shows autoradiographs, show-
ing the phosphorylation status of the GST-ATF2 fusion protein used as a substrate to measure the kinase activities in the JNK and p38 immunoprecipi-
tates. The bottom panel shows a graphical presentation obtained after scanning the corresponding autoradiographs. AU, arbitrary units.
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RXR/PPARg heterodimer in colon inflammation, they
did not address any of the possible downstream mechanisms
involved in this protective effect. Intestinal inflammatory
cytokines and the NF-kB and MAPK pathways were eval-
uated in mice killed 2 d after TNBS administration. Low
concentrations of TNF-a and IL-1b mRNA were present
in the colon of control mice (Fig. 7). 2 d after induction of
colitis by TNBS, TNF-a and IL-1b mRNA were signifi-
cantly induced, compatible with a major inflammatory re-
action (Fig. 7). In contrast, the preventive administration of
rosiglitazone (at 20 mg/kg/d), troglitazone (at 150 mg/kg/
d), LG101305 (at 20 mg/kg/d), and the simultaneous ad-
ministration of both rosiglitazone and LG101305 (both at
the dose of 1 mg/kg/d) normalized TNF-a and IL-1b
mRNA concentrations in the colon (Fig. 7 and Table II).
Conversely, the more intense macroscopic and histologic
colitis observed in PPARg1/2 and RXRa1/2 mice were
associated with a significant increase in the levels of TNF-a
and IL-1b mRNA, compared with wild-type mice with
colitis (data not shown).
Furthermore, in control mice killed 2 d after administra-
tion of 50% ethanol or a saline solution, low levels of nu-
clear NF-kB DNA binding activity, as well as of JNK and
p38 activities, were observed in colon protein extracts (Fig.
8). 2 d after TNBS administration, NF-kB DNA binding,
JNK, and p38 kinase activities were strongly induced (Fig.
8). Preventive administration of rosiglitazone was associ-
ated both with an important decrease of the activity of NF-
kB DNA binding, JNK, and p38 activities, suggesting the
involvement of MAPKs in TNBS-induced intestinal in-
flammation in mice (Fig. 8).
Discussion
Intrarectal administration of TNBS to mice provokes a
severe colitis, which represents a well-validated model that
has many macroscopic and histologic similarities to IBD in
human. These similarities include the presence of granulo-
mas, mucosal infiltration of neutrophils, mediated at least in
part by TNF-a and IL-1b overexpression, and activation
of the NF-kB pathway (22–25). Earlier studies have shown
that TNBS-induced colitis responds favorably to many of
the current therapies for IBD such as sulfasalazine or 5-ami-
nosalicylic acid (26), glucocorticoids (27), cyclosporin (28),
and anti–TNF-a antibodies (23). In view of the high level
of expression of PPARg in the colon (16, 29, 30) and the
reported antiinflammatory effects of activation of PPARg
(5, 6, 31), we have analyzed the contribution of RXR/
PPARg heterodimers on intestinal inflammatory responses.
As the RXR/PPARg heterodimer is “permissive” and can
be activated both by PPARg or RXR ligands, we first an-
alyzed whether administration of specific synthetic PPARg
or RXR agonists attenuated TNBS-induced colitis. Con-
sistent with the work of Su et al. (7), administration of
PPARg agonists, such as rosiglitazone or troglitazone to
TNBS-treated animals, attenuated the inflammatory re-
sponse. These results confirm that PPARg ligands have an-
tiinflammatory effects in the intestine. Recently, two stud-
ies have shown unequivocally that PPARg expression by
macrophages is not required for PPARg ligands to exert
their antiinflammatory effects (32, 33). This absence of di-
rect effects of PPARg has only been shown on macrophage
biology and not in other cells involved in the inflammatory
reaction. Therefore, these observations suggest that the
ability of thiazolidinediones to suppress TNBS-induced
colitis which involved numerous cells such as macrophages
but also lymphocytes, neutrophils, mast cells, eosinophils,
and epithelial cells may be mediated at least in part through
a different target. The rexinoid LG101305 also had potent
antiinflammatory effects in the intestine. Furthermore, si-
multaneous administration of both PPARg and RXR
ligands had a markedly synergistic beneficial effect on coli-
tis, enabling a significant dose reduction for each agonist.
Further evidence in support of the implication of the
RXR/PPARg heterodimer in the protection against colon
inflammation came from the characterization of PPARg1/2
and RXRa1/2 mice, both of which were more suscepti-
ble to TNBS-induced inflammation. Taken together, our
studies, with synthetic RXR and PPARg agonists and with
heterozygous deficient mice, show that activators of the
RXR/PPARg heterodimer might exert a direct and indi-
rect control of inflammatory responses in the intestine.
Furthermore, these data suggest that the synergistic antiin-
flammatory effect of RXR and PPARg agonists could be
beneficial in a clinical setting, as it might avoid adverse
events often encountered when these agonists are used in
monotherapy at higher doses.
The persistence of inflammation in deeper layers of the
colon in some animals treated with PPARg and RXR ago-
nists, despite the repair of mucosal lesions, is particularly in-
teresting. The absence of histologic improvement in the
deeper layers of the colon could be related at least in part to
the preferential expression of PPARg in the colonic mu-
cosa (30) and its absence in the other layers of the colon
(more particularly the muscular layer). Thus, activators of
the RXR/PPARg heterodimer might exert antiinflamma-
tory effects in the mucosa which selectively expresses this
heterodimer, and indirectly protects the deeper colon layers
against damage by the preservation of the integrity of the
mucosal barrier. Further confirmation of this possibility
would require the study of animals in which activity of the
RXR/PPARg heterodimer was specifically eliminated in
the intestinal mucosa.
The precise mechanisms by which activation of the
RXR/PPARg heterodimer negatively regulates intestinal
inflammation remains to be elucidated (31), but our data
suggest an involvement of both the NF-kB and stress ki-
nase pathways. Many studies have suggested an important
pathogenic role for TNF-a and IL-1b in the pathophysiol-
ogy of TNBS-induced colitis through the recruitment of
polymorphonuclear cells in the colon (34, 35). This possi-
bility is supported by the overexpression of these cytokines
in TNBS-induced colitis, the improvement in disease se-
verity after the neutralization of TNF-a and IL-1b in vivo,
the absence of chronic TNBS-induced colitis in TNF-a
knockout mice, and the development of lethal pan-colitis
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upon TNBS administration in TNF-a transgenic mice
(23). In vivo, the predominant role of NF-kB during
colonic inflammation has been demonstrated in TNBS-
induced colitis and in spontaneous colitis of IL-10–defi-
cient mice (22). It is generally believed that the signal trans-
duction pathways activated in response to TNF-a and IL-1b
initiate NF-kB activation through the NF-kB–inducing
kinase (NIK) signaling pathway (36, 37) and the activation
of two IkB kinases, IKK-1 and IKK-2, which phosphory-
late IkB, leading to its degradation (38). Nonetheless, sev-
eral reports also demonstrate an involvement of members
of the MAPK pathway such as MAPK kinase (MEKK)1
(39–42) and JNK or p38 MAPK in the activation of NF-
kB (8–10). In addition, concomitant activation of the
JNK/p38 MAPK and NF-kB pathways has been observed
in several cell types, including macrophages (43–46). De-
spite this suggestive role of stress kinase in NF-kB activa-
tion, the involvement of the MAPK pathway in chronic
intestinal inflammation has been neglected. In this study,
we demonstrated that NF-kB, JNK, and p38 are activated
concomitantly during TNBS-induced intestinal inflam-
mation in mice and that the activation of both pathways
can be attenuated by activation of RXR/PPARg het-
erodimers. Considering the ambiguous relationships be-
tween NF-kB activation and the MAPK signaling path-
ways (47–50), our observations suggest that activation of
both signaling pathways can lead to colon inflammation.
In conclusion, the data obtained with TNBS-induced
colitis in mice, an animal model having similarities with
IBD in humans, support the existence of an important anti-
inflammatory action of RXR/PPARg heterodimers in the
intestine. Our data further suggest that the simultaneous
administration of synthetic PPARg and RXR agonists
could represent an attractive therapeutic strategy for the
treatment of IBD. In addition, they question the possible
impact of changing dietary habits on the increased preva-
lence of IBD and suggest that beneficial effects could be
expected from changes in diet.
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